Invest In The Future Of Psychedelic Medicine

🍄 Final Pre-IPO Equity Round Closes On July 26th
🍄 Definitive Agreement Entered for $382M Merger
🍄 Join 10,500 Existing Shareholders Who Invested Over $21.5M
🍄 Invest at the Same Valuation as Last Round (closed in March)
🍄 Minimum Investment of $2,470 / $4.94 Per Share

Sign Up For Future
Investment Opportunities

Zero spam. Unsubscribe at any time.

Final Pre-IPO Equity Round Ends In:

Help Us Bring Natural Psychedelic Medicine To The Market

Don’t miss out on your last chance to invest and join EI. Ventures’ mission to help millions of people worldwide struggling with mental illness. Join the ‘farmaceutical’ revolution to create fast and affordable access to 100% natural, whole-plant psychedelic therapies.

Our Mission

We are building the natural psychedelics movement that is open-sourced to the world. Our team of scientists, healers, and conscious investors are changing the narrative around psychedelic therapy so that our gold-standard treatment technology and delivery system can move through FDA trials towards legalization. We want to provide people with a safer and more efficient path to self-improvement so that they can overcome challenges and move forward with higher levels of self-acceptance and a more attuned perspective.

Our Story

We started our journey over 12 years ago in Los Angeles, bringing healing modalities to a growing community of individuals curious about alternative paths to health and wellness. Then came the island of Maui, Hawaii, where we connected with farmers, chemists, and iconic leaders of psychedelic medicine to explore the power of the plant and natural therapies that unlock the mind and heal the soul. EI. Ventures was born out of a mission of conscious, sustainable investing and community building.

Plant-powered therapies, delivered by nature.

EI. Ventures’ is on its way to becoming the world’s leading source for therapy powered by nature. We are building a community and educational platform around the use of functional and psychedelic mushrooms to address a growing mental health crisis.

Psychedelic Therapies

Wellness Products

Web3 Solution
to Mental Health

Mental Health Statistics

Our ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic.


people suffer from depression worldwide


people suffer from PTSD worldwide


people suffer from substance abuse worldwide

1 in 5

American adults suffer from a form of mental illness


of people affected by mass conflicts have PTSD


increase in OUD diagnosis in the U.S. from 2010-2016


The estimated cost of depression to the global economy


Estimated global cost of mental health conditions in 2030 by the World Economic Forum(up from $2.5 trillion in 2010)


people die every day from opioid abuse

Our Solutions

Our suite of mental wellness products and services was designed for the prevention, reversal, and management of chronic mental health disorders.

Our platform will provide an integration of novel formulations including: Botanical Psychedelic API, Mushrooms optimized for nootropic support, and Tele-psychiatry and wellness apps

This suite of products and services aims to tackle multiple indications within the spectrum of mental disorders.

Functional Mushrooms

MANA Nutraceuticals

Our Mana line of nutraceuticals will be derived from different non-psychoactive medicinal mushrooms. These exclusive formulations will be engineered using a unique process for enhanced bioavailability and efficacy.

They are for everyday use and target the following:

  • Cognition and Memory
  • Immunity
  • Energy and Vitality
  • Mood, Sleep, and Weight Loss
  • Mental and Physical Optimization
  • Joint and Muscle Discomfort

These visuals are provided for illustrative purposes only. The final product may differ entirely from the visual.

Our Flagship Psilocybin Formulation

Psilly Patch

Psilly is our psilocybin-based formulation and flagship product. The formulation starts with natural fungal extracts, which is our nano super psilocybin API compound. We intend to process these extracts via our proprietary methods.

  • We believe a minimal effective dose (MED) of Psilly will have a negligible hallucinogenic effect while still providing patient with a psychedelic experience

  • Little to no side effects expected with no “hangover” feeling post-consumption

  • 1-3 hour active period with the ability to continue micro dosing with small amounts

These visuals are provided for illustrative purposes only. The final product may differ entirely from the visual.

Road to FDA Approval

Our psychedelic formulations to go down the FDA pipeline are for the following potential indications: PTSD, Depression, and Substance Abuse Disorder.

The first drug candidate is our patent pending product, the Psilly Patch which is our Psilocybin formulation.

These visuals are provided for illustrative purposes only. The final product may differ entirely from the visual.

Psilocybin Gaining Support Across the U.S.

Over 150 cities and several states consider psilocybin reforms, Ei.Ventures is poised to come to market wherever it is within the letter of the law.

Merger Update

Here is the latest on our $382M definitive merger agreement with Mycotopia Therapies. We will continue to update our shareholders and the market on our path to a NASDAQ listing, as well as other material updates as launches into the market:

May 19, 2022 from Miami, Florida and Maui, Hawaii – Ei.Ventures Inc. (“Ei”) today announced an update on the previously announced merger with Mycotopia (OTC: TPIA)


Ei has executed a definitive agreement with Mycotopia bringing the two entities together under as the companies move forward with their plan of uplisting to the NASDAQ stock exchange. will be the parent entity owning all the assets of Ei and Mycotopia.

As previously reported, Ei shareholders will receive shares in based upon a valuation of $360 Million (subject to adjustment as set forth in the merger agreement) at the close of transaction. Mycotopia shareholders will receive shares in based upon a valuation of more than $23 million at the close of the transaction.

The companies anticipate closing the transaction on or about July 30, 2022.


Upon the closing of the transaction, will have a market value of approximately $383 million.

As Ei founder and CEO David Nikzad explains: “Of all the companies out there, we were most excited by Mycotopia. The areas where they specialize and have been working complement the Ei mission and business plan perfectly. They are helping us bring our products from the land back to the land. A journey my cofounder Jason Hobson and I began over 20 years ago. In Hawaii, we call this “going back to aina.”

Since psilocybin is legal in Jamaica and the Netherlands, Ei will be able to leverage Mycotopia’s presence in both countries as a launching pad for its psilocybin consumer and medicinal product lines. This includes Odyssey Elixir, Psilly patches, and the Mana nutraceuticals line as well as any products developed in the future. Mycotopia will be able to leverage Ei’s proprietary formulations, as well as the benefits from the recent strategic investments in Odyssey Wellness LLC Elixir and Avicanna (OTC: AVCNF).

Mycotopia founder and CEO Ben Kaplan stated: “The combination of Ei and Mycotopia is a perfect combination of synergies. We are in markets where psilocybin is already legal. And Ei has been at the forefront of psychedelic thought, formulation, and implementation since the early days. Combining forces makes sense for the shareholders of both companies, as well as the millions of people that could potentially benefit from our combined product pipeline.” will continue to expand in physical markets as well as in the digital realm – building on Ei’s recent purchase of hundreds of acres in the Metaverse. Combining the physical and digital will help Ei achieve its founding mission statement: to help over one billion people with natural, non-synthetic remedies derived from nature – not a lab.

Ei and Mycotopia will continue to update shareholders and the market on the path to a NASDAQ listing, as well as other material updates as launches into the market.

Aloha on behalf of the Board,
David Nikzad
Founder and CEO, Ei.Ventures Inc.

About Ei.Ventures Inc.:

Ei.Ventures Inc. is an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology. Ei is leveraging blockchain, emerging technologies and the Metaverse to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. It is the goal of Ei to utilize the development of these technologies, to create a safe, efficient, and secure way to provide telehealth services in general and specifically to the psychoactive therapeutics. Additional information on Ei can be found on the Ei’s website at:

About Mycotopia Therapies Inc. (TPIA):

Mycotopia Therapies Inc. focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia can be found on Mycotopia’s website at:

View this press release on:

Offering Highlights

Per Share
Minimum Investment
Existing Shareholders
Raised in Previous Round

Ready to Join the Ei Ohana, family?


For U.S. based investors, please note this round is open to accredited investors only.

For international investors, you are not required to meet the U.S. accredited investor definition.

Not sure if you’re accredited? In the U.S., an accredited investor is defined as a person with:

  • Net worth over $1 million, excluding your primary residence (individually or with spouse or partner).
  • Income over $200,000 (individually) or $300,000 (with spouse or partner) in each of the prior two years, and reasonably expects the same for the current year.

Schedule a Call With Us

Our Team

David Nikzad

CEO & Co-Founder

Jason Hobson

COO and Co-Founder

Brian Keane

Mergers & Acquisitions

Linda Strause, Ph.D

Director of Clinical Operations

Dar Fazulyanov

Chief Financial Officer

Meghan Brennan

Legal Counsel

A Web3 Solution to Mental Health

We believe in non-pharmacological intervention to support mental health by utilizing next-generation technology.

Across web3 and the growing metaverse, we are creating virtual resources for people to access information, perspectives, and guided mental health therapy on plant-based psychedelic treatments and other alternative routes to self-improvement.

Following our acquisition of a notable virtual land plot in the popular Sandbox metaverse, we are hard at work building and ideating around what mental health therapy looks like in virtual worlds.

Frequently Asked Questions

I made a typing mistake when signing up, how can I find a remedy for it?2022-06-18T18:26:16-07:00

Sign into your DealMaker account, go to Your Profile to change your name and email.

How do I contact the EI Ventures for assistance?2022-06-18T18:26:05-07:00
Will you send a stock certificate or other ‘proof’ of investment?2022-06-18T18:25:38-07:00

Yes, a fully executed subscription agreement will be sent to you once you have funded your investment and our Compliance Team has cleared your account of any anti-money laundering exceptions

What happens if I get locked out of my DealMaker account?2022-06-18T18:39:25-07:00

DealMaker is our payment/funding portal partner where investors will complete their investments.

If you get locked out for any reason, please contact

I’m having trouble investing, my payment went through, but was rejected on your end. Why is this happening and how could I secure my investment?2022-06-18T18:24:22-07:00

Please contact your credit card company explaining that you meant to make this purchase. You can then reprocess your payment on your DealMaker account.

What account types can I invest with?2022-06-18T18:23:36-07:00

Individual, joint, company, 401k/IRA (check with your custodian).

Are there are any warrants involved in this offering?2022-06-18T18:23:13-07:00

No warrants are involved. Shares are $4.94 which is the same price we issued shares for in our Reg A+ offering that closed in March 2022. We wanted to give one last opportunity for investors to get in without raising the share price.

Do you need to be an accredited investor?2022-06-18T18:21:30-07:00

For US and Canadian residents – we are only able to accept accredited investors at this time. For all other countries, we do not have an accreditation requirement.

If you are not an accredited investor, you are free to sign up using any of the forms on this page and simply indicate that you are not an accredited investor – we will notify you if and when any future investment opportunities become available for non-accredited investors.

What payment options are available?2022-06-18T18:18:49-07:00

What payment options are available?

How long does payment process time take?2022-06-18T18:18:40-07:00

5-7 business days

Who is the transfer agent?2022-06-18T18:18:15-07:00

Odyssey Trust

When will the fully executed subscription agreement be sent?2022-06-18T18:17:58-07:00

The subscription agreement will be sent in a period of ten business days. If there are any AML (anti-money laundering) issues, this process may be delayed.

How can I place my investment?2022-06-18T18:17:22-07:00

For US investors, click here – [INSERT DEALMAKER LINK]

For international investors, click here – [INSERT DEALMAKER LINK]

Sign Up For Future
Investment Opportunities

Zero spam. Unsubscribe at any time.

As seen in

Go to Top